Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  therapeutic tumor infiltrating lymphocytes
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 58 for your search:
Start Over
Phase II/III Randomized Study of CD8+ TIL/IL-2 for Metastatic Renal Cell Carcinoma (Summary Last Modified 09/95)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AIS-1061-9320, NCI-V95-0689
Phase I/II Chemoimmunotherapy with IL-2/CY, plus Tumor Infiltrating Lymphocytes in Selected Patients and alpha-Interferon in Some Patients, in Treatment of Advanced Refractory Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: any age
Sponsor: NCI
Protocol IDs: NCI-86-C-183E, NCI-T86-0225N, T86-0225
Phase I/II Study of rIL-2/TIL plus CTX in Patients with Metastatic Carcinoma, Sarcoma, or Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: NBSG-8720, NCI-V88-0615
Phase I/II Study of In Vivo-Primed TIL in Combination with IFN-A/IL-2 in Patients with Metastatic Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: UCLA-9102071, UCLA-UO-91-1, NCI-B91-0006, B91-0006
Phase I/II Study of TIL/IL-2 in Patients with Advanced Melanoma (Summary Last Modified 12/92)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: PCI-9038, NCI-T91-0133O, T91-0133
Phase I/II Study of In Vitro-Expanded CD8(+) TIL in Combination with IL-2 or IL-2/IFN-A in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 07/93)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: UCLA-9102052, NCI-V91-0217
Phase II Trial of TIL/IFN-A/IL-2 in Patients with Advanced Cancer (Summary Last Modified 01/93)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: NBSG-9201, NCI-V92-0156
Activated White Blood Cells in Treating Patients Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Stage II or Stage III Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: J0770 JHU, P30CA006973, JHOC-J0770, J0770, NCT00566098
Biological Therapy in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: 1017.01, FHCRC-1017.01, NCI-V96-0920, CDR0000064846, NCT00002786
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000256870, MSGCC-0065, UPCC-6401, NCI-V02-1709, NCT00046852
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, NIH WGMCC
Protocol IDs: 030162, 03-C-0162, NCI-5855, CDR0000304438, NCT00062036
Phase II Study of Prenephrectomy IFN-A and Postnephrectomy IFN-A/IL-2/TIL in Metastatic Renal Cell Carcinoma (Summary Last Modified 05/98)
Phase: Phase II
Type: Treatment
Status: Completed
Age: over 16
Sponsor: Other
Protocol IDs: STLMC-BRM-93006, NCI-V94-0365
Phase II Pilot Study of Tumor-Derived Activated Killer Cells with IL-2 and IFN-A for Advanced Cancer (Summary Last Modified 09/97)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NBSG-9401, NCI-V94-0455
Phase II Pilot Study of Tumor-Derived Activated Killer Cells Administered with IL-2/IFN-A for Metastatic Cancer (Summary Last Modified 09/97)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NBSG-9403, NCI-V94-0457
Phase II Pilot Study of Intraperitoneal Adoptive Immunotherapy Using TIL Primed with Intraperitoneal IFN-G/IL-2 for Epithelial Ovarian Cancer (Summary Last Modified 01/2000)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: MDA-GYN-94001, NCI-T94-0052D, T94-0052
Phase II Study of TMX/CDDP/DTIC/IFN-A Followed by TIL/IL-2 for Advanced Melanoma (Summary Last Modified 01/98)
Phase: Phase II
Type: Treatment
Status: Completed
Age: over 16
Sponsor: Other
Protocol IDs: STLMC-BRM-93005, NCI-V94-0505
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000064192, NCI-95-C-0105A, NCI-T94-0096N, T94-0096, NCT00019084
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 990158, 99-C-0158, NCI-99-C-0158, NCI-T99-0078, T99-0078, NCT00019942, NCT00001832
Phase II Study of IL-2 plus Tumor Infiltrating Lymphocytes Grown in a Hollow-Fiber Culture Device to Treat Patients with Advanced Cancer (Summary Last Modified 12/98)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 2 and over
Sponsor: NCI
Protocol IDs: NCI-90-C-0029A, NCI-T89-0227N, T89-0227
Phase II Study of Tumor Infiltrating Lymphocytes in Patients with Advanced Melanoma or Renal Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 15
Sponsor:
Protocol IDs: STLMC-BRM-89-0001, NCI-V90-0025
Phase II Study of IFN-A/IL-2/TIL Following In Vivo IFN-A Priming of TIL in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 01/91)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: UCLA-8908317, NCI-V90-0174
Start Over